<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Primary lung graft dysfunction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Primary lung graft dysfunction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Primary lung graft dysfunction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Vivek N Ahya, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramsey R Hachem, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3321595326"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Primary graft dysfunction (PGD) is a type of severe lung injury that occurs within the first 72 hours of lung transplantation and is the most common cause of early mortality. The pathophysiology, risk factors, diagnosis, grading, and strategies to prevent and treat PGD are reviewed here. Other lung transplant-specific complications and management considerations are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/4651.html" rel="external">"Lung transplantation: Procedure and postoperative management"</a> and  <a class="medical medical_review" href="/z/d/html/4657.html" rel="external">"Physiologic changes following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4662.html" rel="external">"Airway complications after lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">"Fungal infections following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">"Viral infections following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/15396.html" rel="external">"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a> and  <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection"</a> and  <a class="medical medical_review" href="/z/d/html/4661.html" rel="external">"Induction immunosuppression following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/4653.html" rel="external">"Pleural complications in lung transplantation"</a>.)</p><p class="headingAnchor" id="H414437850"><span class="h1">DEFINITION AND GRADING</span><span class="headingEndMark"> — </span>PGD is defined by the presence of diffuse pulmonary opacities on thoracic imaging and hypoxemia without other identifiable cause, developing in the first 72 hours after lung allograft implantation [<a href="#rid1">1</a>]. The typical histopathologic pattern of PGD is diffuse alveolar damage.</p><p>The definition of PGD was updated in the 2016 consensus report of the International Society of Heart and Lung Transplantation (ISHLT)'s working group on PGD. Key features of the definition include the following  (<a class="graphic graphic_table graphicRef78107" href="/z/d/graphic/78107.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The presence of PGD requires radiographic findings consistent with pulmonary edema and its severity is modeled in part on the definition of the acute respiratory distress syndrome (ARDS) [<a href="#rid2">2</a>] (see  <a class="medical medical_review" href="/z/d/html/1637.html" rel="external">"Acute respiratory distress syndrome: Clinical features, diagnosis, and complications in adults"</a>). PGD grades are determined by the ratio of the partial pressure of arterial oxygen (PaO<sub>2</sub>)/fraction of inspired oxygen (FiO<sub>2</sub>), also called P/F ratio. If the PaO<sub>2</sub> is not available, the oxygen saturation (SpO<sub>2</sub>)/FiO<sub>2</sub> or S/F ratio may be utilized instead [<a href="#rid1">1,3</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PGD grade 0 (no PGD): no opacities on chest radiograph</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PGD grade 1:P/F ratio &gt;300 or S/F ratio &gt;315</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PGD grade 2:P/F ratio = 200 to 300 or S/F ratio = 235 to 315</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>PGD grade 3: P/F ratio &lt;200 or S/F ratio &lt;235</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PGD is assessed at four time points, starting at the time of reperfusion of the second lung (T0), and then at 24, 48, and 72 hours (T24, T48, T72).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The PaO<sub>2</sub>/FiO<sub>2</sub> is ideally measured on a positive end-expiratory pressure (PEEP) of 5 cm H<sub>2</sub>O at FiO<sub>2</sub> 1.0; correction may be needed for high altitude.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Use of extracorporeal lung support (ECLS) with bilateral pulmonary edema on chest radiograph should be graded as grade 3, and ECLS use should be documented. The use of ECLS for nonhypoxic indications without pulmonary edema on chest radiograph should be considered ungradable.</p><p></p><p class="headingAnchor" id="H4086315569"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>The incidence of PGD is reported to be in the range of 40 percent overall and 25 to 30 percent for PGD grade 3 at 48 and 72 hours [<a href="#rid4">4,5</a>]; it remains the leading cause of early mortality after lung transplantation [<a href="#rid6">6-8</a>].</p><p class="headingAnchor" id="H3420042929"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of PGD is incompletely understood but is thought to be the end-result of multiple different types of injuries to the allograft that begin prior to harvesting of the donor lung. Brain death results in hemodynamic instability, inflammation, hypercoagulability, and hormonal deficits that may contribute to end-organ damage. Additionally, aspiration, pulmonary embolism, fat emboli, traumatic injury, and cardiac dysfunction may also cause organ dysfunction prior to harvesting. The organ retrieval process may directly cause lung injury due to the deleterious effects of cold ischemia (during transport) and subsequent inflammation triggered by graft rewarming, implantation, and reperfusion. Transfusion of blood products and mechanical ventilation may also contribute to development of PGD  (<a class="graphic graphic_figure graphicRef57115" href="/z/d/graphic/57115.html" rel="external">figure 1</a>) [<a href="#rid9">9-15</a>]. A few of these issues are reviewed in more detail below:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor brain death </strong>– Brain death triggers pathophysiologic derangements that lead to hemodynamic instability, hormonal changes, systemic inflammation, and hypercoagulability, increasing risk of developing organ damage [<a href="#rid11">11,16-19</a>]. For example, levels of the pro-inflammatory cytokine interleukin (IL)-8 increase significantly after brain death [<a href="#rid19">19</a>]. Analysis of bronchoalveolar lavage (BAL) fluid or tissue biopsy samples from lung transplant recipients of organs from brain-dead donors has also shown increased levels of IL-8 in patients who develop PGD, with higher levels associated with more severe PGD grades and increased mortality [<a href="#rid20">20</a>]. Despite optimal donor management and donor lung assessment, lung injury may not be recognized before transplantation and manifest post-transplantation as PGD [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/z/d/html/4664.html" rel="external">"Lung transplantation: Deceased donor evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/114018.html" rel="external">"Management of the deceased organ donor"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung retrieval/cold storage</strong> – To mitigate the deleterious effects of ischemia (due to absence of blood flow) during organ transport, the donor lung is flushed with preservation fluid at 4 to 8ºC during organ retrieval. While cold storage helps preserve lung allograft integrity, a number of injurious events may occur during this phase, especially if duration is prolonged [<a href="#rid22">22</a>]. While the acceptable limits of ischemic time are not certain, most-transplant centers try to limit cold ischemic times to less than eight hours [<a href="#rid9">9</a>]. The process of lung retrieval is unique in that the lung is partially inflated with a fraction of inspired oxygen (FiO<sub>2</sub>) of 0.3 to 0.5 during storage [<a href="#rid9">9</a>]. This permits oxygen consumption and maintenance of aerobic metabolism during the ischemic period. While this may be beneficial to cellular function, studies have also reported increased production of reactive oxygen species (ROS), which may increase lung injury [<a href="#rid15">15</a>]. Additional information on lung retrieval techniques, types, and composition of preservation solutions, is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung implantation and reperfusion</strong> – Ischemia-reperfusion injury after graft implantation and reperfusion is thought to have a central role in the development of PGD [<a href="#rid23">23</a>]. During the ischemic period, pulmonary endothelial cells generate ROS and nitrogen species that contribute to oxidative injury. With reperfusion, numerous cellular mechanisms are activated or amplified that then activate the innate immune system and trigger release of inflammatory cytokines and other mediators. This process ultimately increases endothelial cell permeability, damages alveolar epithelial cells, increases pulmonary vascular resistance, and reduces surfactant production leading to accumulation of edema fluid, decreased lung compliance, and impaired gas exchange [<a href="#rid23">23-26</a>].</p><p></p><p class="headingAnchor" id="H2085865192"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Over the last decade, multiple studies have identified risk factors for PGD. Donor-, recipient-, and transplant procedure-related variables have been implicated [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H348076985"><span class="h2">Donor-specific risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor smoking history</strong> – Donor history of cigarette smoking has been reported in several studies to be an important risk factor for PGD [<a href="#rid6">6,7,27,28</a>]. In fact, any donor smoking history was found to be independently associated with PGD in a large multicenter United States-based prospective cohort study of 1255 patients [<a href="#rid6">6</a>]. In a study of 1295 lung transplants performed in the UK, donor smoking history was an independent risk factor for poorer three-year survival [<a href="#rid29">29</a>]; however, this effect on mortality was not seen in a separate cohort from the United States in which smoking history was more precisely defined by including measurement of urinary concentrations of nicotine metabolites [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1">While donor cigarette smoking may be a modifiable risk factor (ie, not using these donors for lung transplantation), widespread avoidance of these donors could result in greater harm, as almost 40 percent of lung donors in both the United States and UK studies had a smoking history or urinary markers of nicotine exposure [<a href="#rid28">28,29</a>]. While avoiding use of donors who smoke may be beneficial to a specific recipient's risk of PGD, the net impact of excluding these donors would significantly diminish the number of donor lungs available for transplantation and increase waitlist mortality. Furthermore, when comparing survival from the time of placement on the transplant list, the survival probability after receiving an allograft from a donor with a smoking history is greater than remaining on the waitlist and waiting for a nonsmoking donor [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1">Further studies are needed to better understand why smoking is detrimental to early graft function, whether or not there is a dose effect, and if there are certain recipients who would be at prohibitively high risk for developing PGD or poor outcome from use of these donors. In a study of 298 donor lungs deemed unsuitable for use in transplantation, lungs from current smokers had increased pulmonary edema, reduced alveolar fluid clearance rates, and higher levels of interleukin (IL)-8 in bronchoalveolar lavage (BAL) fluid when compared with nonsmokers [<a href="#rid30">30</a>]. Notably, there appeared to also be a dose-dependent effect with lungs from donors with a less than 20-pack-year history, demonstrating better alveolar fluid clearance rates than lungs from donors with a greater smoking history [<a href="#rid30">30</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor alcohol use</strong> – High alcohol consumption increases the risk for acute respiratory distress syndrome (ARDS) [<a href="#rid31">31,32</a>]. Thus, it's not surprising that a donor history of heavy alcohol use has been associated with PGD grade 3 [<a href="#rid33">33</a>]. In one study, this risk was almost ninefold higher compared with donors without alcohol use [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor age</strong> – While earlier studies reported donor age to be an important risk factor for PGD, subsequent studies suggest that the impact of donor age may not be as great as initially reported. In an analysis of data from the multicenter Lung Transplant Outcomes Group (LTOG) of 1212 patients, donor age between 18 and 64 was not significantly associated with PGD risk [<a href="#rid35">35</a>]. The risk of using donors at the extremes of age is uncertain and may confer greater risk [<a href="#rid7">7</a>]. Notably, a study of 241 recipients transplanted with lungs from carefully selected donors who were greater than 65 years of age showed comparable rates of PGD and one-year survival to patients who had received transplants from younger donors [<a href="#rid36">36</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Donor race, sex, and lung size</strong> – Analyses of the United Network of Organ Sharing (UNOS) registry and the LTOG database have not shown an association between donor race and PGD risk [<a href="#rid6">6,37</a>]. The impact of donor sex or donor–recipient sex mismatch is uncertain, with published reports yielding conflicting results [<a href="#rid7">7,38</a>]. In the previously referenced multicenter study of the LTOG registry, neither sex nor race were identified as independent risk factors for PGD [<a href="#rid6">6</a>]. The increased risk previously attributed to female sex of donors is more likely related to smaller donor organ size than to donor sex [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">The thoracic organs from men are generally (approximately 20 percent) larger than lungs from women [<a href="#rid39">39</a>]. Implantation of oversized allografts has been associated with decreased risk of grade 3 PGD and improved survival among bilateral lung transplant recipients. More specifically, a predicted total lung capacity (pTLC) ratio (donor pTLC: recipient pTLC) greater than 1 was associated with significantly lower rates of grade 3 PGD in LTOG registry subjects [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other probable donor risk factors</strong> – Risk factors that are considered probable include aspiration and chest trauma/lung contusion [<a href="#rid7">7</a>]. Indirect evidence comes from one cohort study of 507 transplanted patients, in which those receiving donor lungs with high levels of total bile acids in large airway bronchial washings (a marker of aspiration, n = 49) had increased risk of primary graft dysfunction (HR 2.4, 95% CI 1.3-4.5) compared with the rest of the cohort [<a href="#rid41">41</a>].</p><p></p><p class="bulletIndent1">Both aspiration and trauma may contribute to extravascular lung water accumulation and increase donor lung weight, which has also been suggested as a risk factor [<a href="#rid42">42,43</a>]. In a retrospective cohort study of 313 lung transplants, greater lung weight (normalized to height) was associated with more frequent PGD grade 3 (28 versus 7.4 percent for lungs in the highest versus lowest two quartiles, respectively, at 24 hours) [<a href="#rid43">43</a>]. Among the 51 lungs transplanted after undergoing ex vivo lung perfusion, 4 experienced PGD grade 3, all of which were in the highest quartile of lung weight postperfusion.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Possible donor-related risk factors</strong> – Certain donor characteristics are considered possible contributors to PGD. These include traumatic brain injury, shorter time from brain death to cold preservation, and prolonged mechanical ventilation [<a href="#rid7">7</a>]. Additionally, donor fat embolism and thromboembolism may be a risk factors for PGD [<a href="#rid44">44</a>]. In one study of 135 recipients, there was a 21- and 5-fold increased risk of developing severe PGD among those who received lungs with fat emboli and thromboemboli, respectively, compared with patients who obtained lungs without these abnormalities [<a href="#rid45">45</a>].</p><p></p><p class="headingAnchor" id="H2336255827"><span class="h2">Recipient-specific risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recipient diagnoses</strong> – Transplantation for idiopathic pulmonary arterial hypertension, diseases complicated by secondary pulmonary hypertension, idiopathic pulmonary fibrosis (IPF), and sarcoidosis have been associated with increased PGD risk [<a href="#rid6">6,7,25,46-48</a>]. Notably, in the multicenter cohort study from the LTOG database, for every increase in mean pulmonary arterial pressure of 10 mmHg, the risk of PGD increased by 30 percent [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obesity</strong> – A large cohort study and systematic review identified elevated recipient body mass index (BMI; ≥25 kg/m<sup>2</sup>) as a risk factor for PGD [<a href="#rid6">6,7,46,49</a>]. In the multicenter LTOG study of 1255 recipients, obesity was associated with a greater than twofold increase in PGD [<a href="#rid6">6</a>]. In addition to weight, higher plasma levels of leptin, a hormone released by adipose tissue with inflammatory properties, has been associated with PGD risk [<a href="#rid50">50</a>]. Distribution of adiposity may also be associated with increased risk. In a study measuring body composition with chest and abdominal CT scans, the volume of subcutaneous but not visceral adipose tissue was associated with PGD risk [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sex, race, and age</strong> – While data are conflicting, it is unlikely that recipient sex, race, or age are important risk factors for PGD. In a pooled, unadjusted, meta-analysis of 13 studies published from 1970 to 2013 and involving more than 10,000 patients, both female sex and African-American descent were associated with higher rates of PGD. Limitations of this study included significant heterogeneity of patient populations, era of transplantation, and PGD definition [<a href="#rid46">46</a>]. In contrast, the multicenter LTOG study of 1255 lung transplant recipients did not identify recipient sex, race, or age as independent risk factors for PGD [<a href="#rid6">6</a>]. Recipient-specific risk factors for patients &lt;18 or &gt;65 years of age have not been clearly identified as data are limited [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genetics</strong> – Polymorphisms in several genes have been associated with PGD risk. These include polymorphisms in long pentraxin-3 (PTX3), IL-17, prostaglandin E2 (<em>PGE2</em>) synthase gene and genetic variations in the Toll interacting protein (TOLLIP) [<a href="#rid52">52-54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Left ventricular diastolic dysfunction</strong> – Echocardiographic parameters of left ventricular diastolic dysfunction have been associated with increased risk of PGD after adjustment for recipient age, BMI, mean pulmonary artery pressure, and pretransplant diagnosis [<a href="#rid55">55</a>]. Elevated left-ventricular end-diastolic pressure (LVEDP &gt;15 mmHg) on pretransplant cardiac catheterization was also associated with PGD grade 3 [<a href="#rid56">56,57</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preformed autoantibodies</strong> – The presence of preformed antibodies to lung-restricted self-antigens (k-alpha-1 tubulin and collagen type V) have been identified as risk factors for PGD [<a href="#rid58">58-60</a>].</p><p></p><p class="headingAnchor" id="H3227555710"><span class="h2">Perioperative risk factors</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiopulmonary bypass</strong> – The use of cardiopulmonary bypass (CPB) is considered an independent risk factor for PGD (odds ratio [OR] 3.4, 95% CI 2.2-5.3) [<a href="#rid6">6,7,46</a>]. The need for CPB may be a marker for greater severity of illness in the recipient; thus, its association with PGD may be confounded by indication. Venoarterial extracorporeal membrane oxygenation (V-A ECMO) is increasingly used as an alternative to CPB for intraoperative cardiopulmonary support [<a href="#rid61">61-63</a>]. A meta-analysis of seven observational studies comparing the two support modalities suggested that rates of PGD as well as other early complications (eg, bleeding, renal failure) were increased in patients receiving CPB when compared with those who had received V-A ECMO intraoperatively [<a href="#rid64">64</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion</strong> – Large-volume intraoperative blood product transfusion is an independent risk factor for PGD [<a href="#rid7">7,65-67</a>]. Transfusion-related acute lung injury (TRALI) mediated by transfused human leukocyte antigen (HLA)-antibodies or anti-granulocyte antibodies in the inflamed allograft has been reported in the setting of PGD [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ischemic time</strong> – Multiple observational studies have found prolonged ischemic time to be a risk factor for PGD in adult recipients. However, a multicenter observational study reported that the incidence of PGD grade 3 at 48 and 72 hours was not associated with ischemic time [<a href="#rid6">6,7</a>]. While the upper limit of safe ischemic times is unknown, standard practice is to limit cold ischemic times to &lt;8 hours. The continued development of ex vivo lung perfusion (EVLP) technologies may expand the duration of safe ischemic times beyond 12 hours [<a href="#rid68">68</a>]. (See  <a class="medical medical_review" href="/z/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation", section on 'Normothermic ex-vivo perfusion (after cold static preservation)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anastomosis time</strong> – Warm ischemia during the implantation process may contribute to reperfusion injury. One retrospective cohort study of 427 patients examined the association between PGD grade 3 and anastomosis time, defined as the time from the end of the ice-cold preservation period to the removal of vascular clamps [<a href="#rid69">69</a>]. One hundred thirty patients (30 percent) developed PGD grade 3 at 72 hours after transplant. Anastomosis time was an independent predictor of PGD grade 3 at 72 hours (OR 1.2 per 10 minutes, 95% CI 1.02-1.4) after controlling for other factors, including age, BMI, intraoperative extracorporeal lung support (ECLS), cold ischemic time, transplant type, and transfusions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FiO</strong><strong><sub>2</sub></strong><strong> during reperfusion</strong> – The fraction of inspired oxygen (FiO<sub>2</sub>) ≥0.4 during reperfusion is associated with an increased risk of PGD at 48 or 72 hours, compared with an FiO<sub>2</sub> &lt;0.4 (OR 1.1 per 10 percent increase in FiO<sub>2</sub>, 95% CI 1.0-1.2) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanical ventilation</strong> – Lung protective ventilation utilizing tidal volumes of 6 to 8 mL/kg calculated utilizing donor rather than recipient ideal body weight has been associated with reduced risk of developing PGD grade 3 and improved one-year survival [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Delayed chest closure</strong> – It is unclear whether delayed chest closure is a risk factor for PGD, a marker for PGD development, or reflects other intraoperative challenges, as delayed chest closure is associated with use of CPB, high transfusion requirement, increased oxygen requirement, and elevated pulmonary artery pressure [<a href="#rid71">71,72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Type of transplant procedure</strong> – In some studies, single lung transplant is associated with a greater risk of PGD (OR 2, 95% CI 1.2-3.3) [<a href="#rid6">6</a>], but other studies have not confirmed this association [<a href="#rid46">46</a>].</p><p></p><p class="headingAnchor" id="H813846176"><span class="h2">Post-transplant factors</span><span class="headingEndMark"> — </span>A number of early post-transplant complications/factors may contribute to the development of PGD or complicate diagnostic assessment. These include aspiration, fluid overload, arterial and venous anastomotic complications, hypotension, mechanical ventilation (particularly the use of high tidal volumes), and pneumonia [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H2616551050"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>The cardinal clinical manifestations of PGD grade 3 are declining oxygenation and diffuse radiographic opacities in the transplanted lung(s) that develop in the first 72 hours following transplant [<a href="#rid1">1</a>]. Other clinical findings typically include decreased pulmonary compliance, increased pulmonary vascular resistance, and intrapulmonary shunting [<a href="#rid1">1</a>].</p><p>The severity of PGD is categorized based on the presence or absence of diffuse opacities on chest radiograph and the ratio of arterial oxygen pressure to inspired oxygen concentration (PaO<sub>2</sub>/FiO<sub>2</sub> [P/F ratio]). This is described in greater detail above  (<a class="graphic graphic_table graphicRef78107" href="/z/d/graphic/78107.html" rel="external">table 1</a>). (See <a class="local">'Definition and grading'</a> above.)</p><p class="headingAnchor" id="H640848292"><span class="h1">DIAGNOSTIC EVALUATION</span></p><p class="headingAnchor" id="H2718309719"><span class="h2">Approach</span><span class="headingEndMark"> — </span>PGD is a diagnosis of exclusion. The diagnostic evaluation of suspected PGD should rule out other conditions that may have a similar clinical and radiographic presentation. These conditions include pulmonary edema secondary to volume overload, left ventricular dysfunction or pulmonary venous outflow obstruction secondary to left atrial thrombus or mechanical issue. Bilateral pneumonia (eg, aspiration), transfusion-related acute lung injury (TRALI), and hyperacute or early antibody-mediated rejection can also present with similar radiographic features.</p><p>The clinician should also consider that more than one condition may be present, as early complications have overlapping clinical and imaging features [<a href="#rid12">12,73</a>] (see  <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a>):</p><p class="headingAnchor" id="H3424431915"><span class="h2">Retrospective crossmatch and HLA antibody testing</span><span class="headingEndMark"> — </span>Laboratory assessment to evaluate for the possibility of hyperacute rejection includes review of the transplant recipient’s immunologic tests for pre-existing HLA antibodies and donor human leukocyte antigen (HLA)-typing. In addition to this "virtual crossmatch," a direct crossmatch is performed at the time of transplant. (See  <a class="medical medical_review" href="/z/d/html/16926.html" rel="external">"Evaluation and treatment of antibody-mediated lung transplant rejection", section on 'Laboratory'</a>.)</p><p class="headingAnchor" id="H1288695079"><span class="h2">Assess volume status</span><span class="headingEndMark"> — </span>Review extent of fluid and blood product resuscitation, total fluid intake and output, urine output, renal function, lactic acidosis, and hemodynamic status. In general, a conservative fluid management strategy that maintains adequate urine output, oxygen delivery, and systemic blood pressure is recommended [<a href="#rid74">74</a>].</p><p class="headingAnchor" id="H1844280470"><span class="h2">Transthoracic echocardiogram</span><span class="headingEndMark"> — </span>An echocardiogram can evaluate left ventricular function and rule out significant pericardial effusion.</p><p class="headingAnchor" id="H785860667"><span class="h2">Transesophageal echocardiogram</span><span class="headingEndMark"> — </span>In patients with severe PGD, consider transesophageal echocardiogram to assess pulmonary venous outflow; thrombus formation at pulmonary venous/left atrial anastomotic site or vascular complications may rarely cause severe pulmonary edema [<a href="#rid75">75-77</a>].</p><p class="headingAnchor" id="H555745163"><span class="h2">Radiographic imaging</span><span class="headingEndMark"> — </span>Review of a conventional chest radiograph can identify new opacities in the lung allograft(s), pleural effusions, hemothorax, and pneumothorax [<a href="#rid47">47</a>]. The most frequent manifestation of PGD is bibasilar ground glass or consolidative opacities that may progress to total lung opacification. Focal opacities may suggest lung infection or atelectasis.</p><p>Chest computed tomography (CT) is frequently obtained to characterize the pattern of parenchymal opacities. CT or ultrasound modalities may be used to differentiate parenchymal opacities from pleural collections [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H2784060218"><span class="h2">Bronchoscopy</span><span class="headingEndMark"> — </span>Bronchoscopy is advised to evaluate for airway obstruction related to mucus or blood clots or bronchial anastomotic abnormalities and to obtain samples of bronchoalveolar lavage (BAL) fluid for microbiologic studies in patients with PGD. Infections that most commonly cause graft failure in the first few days after transplantation are usually bacterial and can originate from the donor or lung recipient, and they may be community-acquired or nosocomial infections. (See  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a>.)</p><p>Infection with community-acquired respiratory viruses (CARVs), may occur at any time. If present in the donor or recipient prior to transplant, CARVs may cause early lung allograft dysfunction [<a href="#rid79">79</a>]. (See  <a class="medical medical_review" href="/z/d/html/13952.html" rel="external">"Viral infections following lung transplantation"</a>.)</p><p>Bronchoscopy is also useful for identifying rare early complications of surgery, such as bronchial anastomotic stricture or dehiscence and whole lung torsion with rotation of the lung around its bronchovascular pedicle [<a href="#rid80">80</a>]. (See  <a class="medical medical_review" href="/z/d/html/4662.html" rel="external">"Airway complications after lung transplantation"</a>.)</p><p class="headingAnchor" id="H4082000686"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of PGD is made in a patient with diffuse pulmonary opacities on thoracic imaging and hypoxemia, developing in the first 72 hours after lung allograft implantation, after exclusion of other identifiable causes. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p class="headingAnchor" id="H2726933574"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis of PGD includes processes that can cause diffuse pulmonary opacities and hypoxemia in the first 72 hours after lung transplantation. One or more of the following processes may coexist with PGD in a given patient.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hyperacute rejection</strong> – Hyperacute rejection occurs in the immediate post-transplant period and is mediated by binding of preformed antibodies to graft antigens (eg, human leukocyte antigen [HLA] or ABO isoagglutinins). Antibodies directed against self-antigens (eg, Collagen V or K-alpha1 tubulin) [<a href="#rid81">81</a>] may also increase PGD risk. Initial evaluation includes review of pre-transplant testing for presence of donor-specific antibodies (DSA) and results of the direct crossmatch. (See <a class="local">'Retrospective crossmatch and HLA antibody testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary edema</strong> – Hydrostatic pulmonary edema can be caused by left ventricular dysfunction or volume overload. The steps in the evaluation include assessment of left ventricular function by echocardiography and optimization of volume status, as described above. Perioperative myocardial injury should be evaluated by laboratory testing. (See <a class="local">'Assess volume status'</a> above and  <a class="medical medical_review" href="/z/d/html/69.html" rel="external">"Perioperative myocardial infarction or injury after noncardiac surgery"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pneumonia</strong> – Bacteria are the most common infectious agents in the immediate post-transplant period despite prophylactic antibiotics. The steps to identify infecting organisms are described above and separately. The empiric antimicrobial regimen is adjusted as needed based on test results. (See <a class="local">'Bronchoscopy'</a> above and  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Occlusion of the venous anastomosis</strong> – Thrombosis of the venous anastomosis should be suspected if one of the transplanted lungs appears opaque on plain chest radiograph. The most useful test to evaluate this possibility is a transesophageal echocardiogram. (See  <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation", section on 'Vascular anastomotic complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pleural fluid or hemothorax</strong> – Postoperative pleural fluid and hemothorax can cause diffuse opacity on a supine chest radiograph, although the opacity is usually more uniform than pulmonary parenchymal disease. Differentiation may require bedside ultrasound or computed tomography. (See  <a class="medical medical_review" href="/z/d/html/4653.html" rel="external">"Pleural complications in lung transplantation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transfusion-related acute lung injury (TRALI)</strong> – (See  <a class="medical medical_review" href="/z/d/html/7926.html" rel="external">"Transfusion-related acute lung injury (TRALI)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspiration</strong> – Aspiration is an uncommon cause of acute respiratory failure in the immediate postoperative period after lung transplantation.</p><p></p><p class="headingAnchor" id="H2952811368"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Most patients with PGD that is less than grade 3 severity improve with conventional supportive treatment. Patients with severe PGD may benefit from more intensive supportive measures.</p><p class="headingAnchor" id="H2695798028"><span class="h2">Initial supportive care</span><span class="headingEndMark"> — </span>The primary treatment strategy for PGD is supportive care, as there is currently no intervention that specifically treats or prevents this complication. As PGD likely represents a form of acute respiratory distress syndrome (ARDS) and has many similar clinical, physiologic, radiographic, and pathologic manifestations, supportive care strategies model those utilized for ARDS treatment [<a href="#rid9">9,25,82</a>]. The general management of ARDS is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1641.html" rel="external">"Acute respiratory distress syndrome: Fluid management, pharmacotherapy, and supportive care in adults"</a> and  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults"</a>.)</p><p>PGD treatment typically involves the following:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Restrictive fluid management strategy</strong> – A restrictive fluid management strategy is often recommended but should ensure adequate end-organ perfusion, oxygen delivery, and hemodynamic stability [<a href="#rid9">9,74</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lung protection ventilation</strong> – Lung protective ventilation, also known as low tidal volume ventilation, is described separately  (<a class="graphic graphic_table graphicRef57072" href="/z/d/graphic/57072.html" rel="external">table 2</a>). Of note, goal tidal volumes should be based on donor rather than recipient ideal body weight [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/1653.html" rel="external">"Acute respiratory distress syndrome: Ventilator management strategies for adults", section on 'Low tidal volume ventilation: Initial settings'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Empiric antibiotics</strong> – As pneumonia is in the differential diagnosis, empiric broad spectrum antibiotics are routinely administered while awaiting microbiologic and histopathologic data. The selection of antimicrobial agents is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunosuppression</strong> – Post-transplant immunosuppression protocols are typically not modified for PGD unless the recipient is deemed to have superimposed infection, acute cellular or antibody-mediated rejection, renal failure, encephalopathy, or other complications that require consideration of alternative immunosuppressive agents or dose adjustment. (See  <a class="medical medical_review" href="/z/d/html/16734.html" rel="external">"Maintenance immunosuppression following lung transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H4252372767"><span class="h2">Refractory hypoxemia</span><span class="headingEndMark"> — </span>For patients with refractory hypoxemia despite optimization of fluid status and ventilator settings, the next step is usually a trial of <a class="drug drug_general" data-topicid="9447" href="/z/d/drug information/9447.html" rel="external">inhaled nitric oxide</a> (iNO) and/or inhaled prostaglandin (eg, <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> [off-label]). Extracorporeal membrane oxygenation (ECMO) is reserved for patients who do not respond to these measures. Retransplantation is generally avoided due to poor outcomes.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pulmonary vasodilators</strong> – iNO or inhaled <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> reduce pulmonary vasoconstriction/pulmonary artery pressure and improve ventilation-perfusion matching, and thereby improve oxygenation [<a href="#rid9">9,83</a>], although evidence demonstrating clinical benefit is limited [<a href="#rid9">9,84,85</a>]. A range of dosing concentrations of iNO has been reported for PGD, but 10 to 20 parts per million (ppm) is most commonly utilized [<a href="#rid86">86</a>]. Of note, methemoglobinemia, a side effect of iNO, may occur rarely when used within acceptable dosing guidelines (5 to 80 ppm) (see  <a class="medical medical_review" href="/z/d/html/7094.html" rel="external">"Methemoglobinemia"</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Extracorporeal life support (ECLS)/extracorporeal membrane oxygenation (ECMO)</strong> – For patients with PGD grade 3 who have refractory hypoxemia (eg, partial pressure of arterial oxygen [PaO<sub>2</sub>]/fraction of inspired oxygen [FiO<sub>2</sub>] [P/F ratio] &lt;100 mmHg) despite optimal medical treatment and ventilator settings, ECMO initiation is recommended [<a href="#rid9">9</a>]. Outcomes are generally better if ECMO is initiated early, preferably within 24 to 48 hours of transplantation [<a href="#rid9">9,87,88</a>].</p><p></p><p class="bulletIndent1">Venovenous (V-V) ECMO is preferred over venoarterial (V-A) ECMO unless hemodynamic support is required. In general, most patients will stabilize on V-V ECMO and it is associated with fewer complications [<a href="#rid9">9</a>]. In a report reviewing a single center’s experience, 96 lung transplant recipients required ECMO support over a 10-year period. All but seven patients were managed with V-V ECMO. Overall, one-year survival was 50 percent. Initiation of ECMO within 48 hours was associated with better outcome [<a href="#rid89">89</a>]. Another study described better survival in patients supported with V-V ECMO: 82 percent at 30 days; 64 percent at one year; and 49 percent survival at five years. By comparison, reported survival with V-A ECMO support was poorer: 56 percent, 40 percent, and 25 percent at 30 days, one year, and five years, respectively [<a href="#rid90">90,91</a>].</p><p></p><p class="bulletIndent1">While early mortality is increased among patients who require ECMO support for PGD, compared with those who do not, other reports suggest that long-term survival is comparable [<a href="#rid92">92,93</a>].</p><p></p><p class="bulletIndent1">A general discussion of outcomes and complications among patients with acute respiratory failure managed at an ECMO center is provided separately. (See  <a class="medical medical_review" href="/z/d/html/1625.html" rel="external">"Extracorporeal life support in adults in the intensive care unit: Overview"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Retransplantation</strong> – Retransplantation has been performed in cases of severe PGD. However, outcomes have generally been poor, and the literature does not support retransplantation for PGD [<a href="#rid94">94</a>]. An analysis of data from the Organ Procurement and Transplantation Network (OPTN) of patients who had undergone retransplantation from January 2001 to May 2006 showed that early retransplantation (within 30 days of initial transplant) had an extremely poor survival, with 1-year survival of only 31 percent [<a href="#rid95">95</a>]. While overall survival following retransplantation has improved [<a href="#rid96">96-98</a>], outcomes after retransplantation for indications other than chronic lung allograft dysfunction (CLAD) remain poor.</p><p></p><p class="headingAnchor" id="H1968231108"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>As with treatment, no specific intervention or targeted therapy has been shown to prevent PGD. Potential strategies to prevent PGD include appropriate donor lung selection and optimal preservation, storage, intraoperative management, and reperfusion techniques. (See  <a class="medical medical_review" href="/z/d/html/4664.html" rel="external">"Lung transplantation: Deceased donor evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>.)</p><p>Approaches to reducing risk of PGD may include the following, although supportive data are limited:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limiting cold ischemia time</strong> – The acceptable limits of cold (4 to 8ºC) ischemic temperatures and times are not known [<a href="#rid9">9</a>]. Ischemic times of up to eight hours are usually considered acceptable, although reported data are conflicting regarding whether longer cold ischemic times are associated with increased PGD risk [<a href="#rid22">22,99</a>] (see <a class="local">'Risk factors'</a> above). The decision to use lungs with ischemic times anticipated to exceed eight hours should be made based on the evaluation of other risk factors while also considering the overall status of the recipient/urgency of transplantation.</p><p></p><p class="bulletIndent1">The introduction of normothermic ex vivo lung perfusion (EVLP) techniques may allow for safer evaluation of lungs with extended cold ischemic times [<a href="#rid68">68,100,101</a>]. However, evidence regarding the potential to successfully and safely recondition lungs with prolonged cold ischemic times prior to EVLP is conflicting [<a href="#rid102">102,103</a>]. A portable EVLP system that allows donor lungs to be immediately supported without need for hypothermic conditions during transport may reduce PGD risks and allow for retrieval of organs across greater geographic distances and travel times. To date, however, there have not been studies comparing rates of PGD stage 3 with static to portable EVLP platforms [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/z/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation", section on 'Normothermic ex-vivo perfusion (after cold static preservation)'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Graft reperfusion rate and pressure</strong> – Controlled perfusion after allograft implantation has been associated with reduced lung injury and PGD risk. Animal studies have shown that lung preservation and storage under hypothermic and hypoxic conditions can cause structural alterations and damage to type I epithelial alveolar cells and pulmonary endothelial cells [<a href="#rid105">105-107</a>]. Rapid reperfusion of the allograft may increase shear stress and augment injury to the vulnerable alveolar capillary barrier, resulting in severe pulmonary edema [<a href="#rid105">105</a>]. Severity of lung injury may be mitigated with gradual reperfusion over a 10-minute period by slowly releasing the pulmonary artery clamp [<a href="#rid108">108</a>]. This approach has been adopted into clinical practice at many centers [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reperfusion FiO</strong><strong><sub>2</sub></strong> – High fraction of inspired oxygen (FiO<sub>2</sub>; &gt;0.40) has been reported to increase risk for PGD, perhaps by mediating hyperoxia-induced oxidative lung injury [<a href="#rid6">6</a>]. This is a potentially modifiable risk factor. Many transplant programs have adopted the practice of graft reperfusion with lower FiO<sub>2</sub> (0.21 to 0.50) [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9447" href="/z/d/drug information/9447.html" rel="external">Inhaled nitric oxide</a><strong> (iNO)</strong> – Inhaled nitric oxide (iNO) does not prevent PGD. Available evidence from three small, randomized studies did not show benefit in preventing PGD when administered at the time of graft reperfusion or shortly afterwards [<a href="#rid109">109-111</a>]. It is not known whether administration of iNO at earlier time points would be beneficial [<a href="#rid112">112</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prostaglandins</strong> – In animal models of lung transplantation, early graft function has been reported to be better when prostaglandin E1 (PGE1, <a class="drug drug_general" data-topicid="8459" href="/z/d/drug information/8459.html" rel="external">alprostadil</a>) is added to preservation solutions [<a href="#rid113">113,114</a>]. This observation has led many clinical centers to use PGE1 as an additive to lung preservation solutions, although human trials to assess clinical benefit have not been performed (see  <a class="medical medical_review" href="/z/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>). </p><p></p><p class="bulletIndent1">The role of the pulmonary vasodilator <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">iloprost</a> (ILO), a synthetic analogue of prostacyclin PGI2, was evaluated in 84 consecutive patients who were transplanted with intraoperative ECMO support. ILO was administered at the time of lung reperfusion. Thirty-two patients received ILO while 52 did not. The investigators utilized propensity score matching and identified two comparable groups of 30 patients and found significantly lower rates of PGD grade 3 on postoperative days 2 and 3 in the ILO-treated group. Additionally, the ILO-treatment group required less mechanical ventilation and had lower lengths of stay in the intensive care unit. Larger randomized studies are needed to confirm this benefit [<a href="#rid115">115</a>]. Separately, administration of inhaled <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> was compared with iNO administration prior to reperfusion of the first transplanted lung in a randomized trial. Rates of PGD stage 3 development were similar in each treatment arm [<a href="#rid116">116</a>].</p><p></p><p class="headingAnchor" id="H2685240005"><span class="h1">EXPERIMENTAL STRATEGIES</span><span class="headingEndMark"> — </span>Significant progress has been made in understanding donor and recipient clinical risk factors and the complex immunologic/inflammatory pathways involved in mediating PGD. Investigation into the impact of genetic variations on cellular and molecular pathways will hopefully lead to trials of more targeted interventions for specific patient populations [<a href="#rid25">25</a>]. The emergence of ex vivo lung perfusion (EVLP) technologies as a potential platform to study novel approaches offers the promise of accelerated development and evaluation of potential therapeutic interventions [<a href="#rid117">117-120</a>].</p><p>Below, a few experimental approaches are briefly highlighted:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenosine</strong><strong> 2A receptor agonists</strong> – Preclinical studies have shown that adenosine 2A receptor (A<sub>2A</sub>R) agonists have anti-inflammatory properties that may attenuate ischemia-reperfusion injury. These effects include reduced activation of invariant natural killer T cells, blunting of the neutrophilic oxidative stress response, and limitation of release of pro-inflammatory cytokines. In a phase 1 trial, the A<sub>2A</sub>R agonist, <a class="drug drug_general" data-topicid="9462" href="/z/d/drug information/9462.html" rel="external">regadenoson</a>, was administered to 14 lung transplant recipients as a 12 hour continuous infusion starting at the time of skin incision [<a href="#rid121">121</a>]. No dose-limiting toxicities were noted. Although this small study was not powered to detect a difference in PGD rates, PGD grade 3 developed in one patient (7 percent), compared with 25 percent of nonstudy patients who were transplanted during the same time period. Further investigation is required to define the therapeutic potential and safety of this agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Surfactant therapy</strong> – Surfactant dysfunction has been shown to occur after ischemia-reperfusion injury [<a href="#rid122">122</a>]. Experimental studies in pigs have found that exogenous surfactant therapy improves pulmonary compliance and alveolar-arterial oxygen gradient after lung transplantation [<a href="#rid123">123,124</a>]. Clinical case reports and an open label trial have also shown promising results using surfactant in patients with PGD [<a href="#rid125">125,126</a>]. In addition, a randomized trial of 15 lung transplant recipients showed a benefit when exogenous surfactant was instilled into donor lungs before retrieval; post-transplant surfactant function and forced expiratory volume in one second (FEV<sub>1</sub>) were both improved relative to control [<a href="#rid127">127</a>]. A meta-analysis of preclinical and clinical studies suggested that exogenous surfactant therapy during lung transplantation improved oxygenation; however, clinical benefit was not established [<a href="#rid128">128</a>]. Larger studies are needed to confirm these preliminary findings. In particular, questions remain about the optimal timing and dosing of therapy [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complement inhibition</strong> – Complement activation is thought to have a significant role in ischemia reperfusion injury [<a href="#rid129">129</a>]. Interventions to inhibit complement have been studied. In a randomized, double-blind, multicenter, placebo-controlled trial of 59 patients, treatment with the soluble complement receptor-1 inhibitor TP-10 showed trends towards reduced time on ventilator and in the intensive care unit, but these findings were not statistically significant. The beneficial effects seemed to be greater in patients who received intraoperative cardiopulmonary bypass support [<a href="#rid130">130</a>]. In another study, nonrandomized lung recipients who developed very severe PGD grade 3 shortly after transplantation were treated with a C1-esterase-inhibitor (C1-INH), which was associated with better outcomes compared with patients with severe PGD who did not receive the study drug [<a href="#rid131">131</a>]. Randomized trials are required to determine benefit of complement inhibition for PGD prevention or treatment.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhanced alveolar fluid clearance</strong> – Impaired alveolar fluid clearance is the hallmark of severe acute respiratory distress syndrome (ARDS) and PGD. Alveolar fluid clearance relies upon the function of amiloride-sensitive epithelial sodium channels (ENaCs) on the apical surface and Na+/K+-ATPase on the basolateral surface of alveolar epithelial cells. AP301 is a synthetic peptide that promotes sodium transport by ENaCs. In a proof-of-concept pilot study, 20 lung transplant recipients with PGD grade &gt;1 received inhaled AP301 or placebo twice daily for seven days or until extubation. Inhalation of AP301 improved gas exchange and led to a shorter duration of mechanical ventilation [<a href="#rid132">132</a>]. Other studies in lung transplantation have not been reported.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inhibition of neutrophil recruitment</strong> – Recruitment of neutrophils following ischemia-reperfusion injury contributes to primary graft dysfunction. Repertaxin is an investigational inhibitor of the chemokine CXCL8 (also called interleukin [IL]-8). CXCL8 has a central role in neutrophil chemotaxis, and it has been hypothesized that repertaxin might prevent neutrophil infiltration and tissue damage and thereby reduce the occurrence of PGD [<a href="#rid133">133</a>]. A clinical in lung transplantation has been completed, however, results have not yet been reported [<a href="#rid134">134</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gene therapy</strong> – Gene-based therapy offers the potential to genetically modify organs to repair injured lungs and withstand stressors that contribute to PGD risk. For example, investigators at the University of Toronto utilized gene-therapy approaches to upregulate production of the anti-inflammatory cytokine IL-10 in damaged human lungs maintained on EVLP. Treatment was delivered by intra-airway administration of an adenoviral vector encoding human IL-10. The investigators demonstrated improved oxygenation and a decrease in lung tissue concentration of pro-inflammatory cytokines [<a href="#rid135">135</a>]. Optimization of gene-delivery systems and diminished inflammatory response to the vectors are still important requirements to move this strategy to the clinical lung transplantation setting [<a href="#rid136">136</a>]. Use of nonviral vectors for gene delivery may be safer alternatives [<a href="#rid119">119</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stem cell therapy</strong> – In animal models, mesenchymal stromal stem cells (MSC) have been reported to attenuate inflammation and reduce lung injury after various insults. In a report of injured pig lungs supported by EVLP, administration of MSCs increased parenchymal concentrations of vascular endothelial growth factor (VEGF) and significantly decreased levels of the pro-inflammatory cytokine IL-8 [<a href="#rid137">137</a>]. Additional studies are underway exploring the role of MSCs, including use of genetically modified MSCs in reducing lung injury [<a href="#rid138">138,139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pirfenidone</strong> – <a class="drug drug_general" data-topicid="88424" href="/z/d/drug information/88424.html" rel="external">Pirfenidone</a> is a drug with anti-inflammatory, antifibrotic, and antioxidant properties. It has been approved for the treatment pf idiopathic pulmonary fibrosis (IPF) [<a href="#rid140">140</a>]. In a rat model of warm ischemia-reperfusion injury, pirfenidone administered before ischemia attenuated lung injury [<a href="#rid141">141</a>]. In a retrospective analysis, patients transplanted for IPF who were treated with pirfenidone (n = 17) pre-transplant were compared with a control group of patients with IPF not treated with pirfenidone (n = 26). Use of pirfenidone was independently associated with less severe PGD, shorter duration of mechanical ventilation, and shorter length of stay in the intensive care unit. Additional studies will likely be forthcoming to evaluate the therapeutic role of pirfenidone [<a href="#rid142">142</a>].</p><p></p><p class="headingAnchor" id="H391008020"><span class="h1">PROGNOSIS</span></p><p class="headingAnchor" id="H3532204685"><span class="h2">Survival</span><span class="headingEndMark"> — </span>Mortality after lung transplant is improving despite an increase in the incidence of PGD [<a href="#rid4">4-6</a>], suggesting that current critical care management better addresses PGD-associated morbidity. For example, in a single-center study of more than 1500 lung transplant recipients, transplantation in the post-lung allocation score (LAS) era (since May 2005) had higher rates of PGD 3 (31.6 percent) [<a href="#rid4">4</a>]. However, this was not associated with increased short-term or long-term mortality compared with the earlier cohort.</p><p>Nevertheless, advances in organ preservation, surgical technique, and perioperative care have not prevented a strong association between PGD and posttransplant morbidity and mortality [<a href="#rid7">7</a>]. In particular, PGD severity at 48 to 72 hours after transplantation correlates with short- and long-term outcomes [<a href="#rid143">143</a>]. In the multicenter Lung Transplant Outcomes Group (LTOG) cohort study, which enrolled 1528 patients between 2011 and 2018, the 26 percent of patients with PGD grade 3 at 48 or 72 hours after transplant had prolonged postoperative mechanical ventilation (nine versus three days) and hospital length of stay (23 versus 18 days) compared with the remainder of the cohort [<a href="#rid5">5</a>]. These patients were also at a 9.8 percent higher absolute risk for death one year after transplant (adjusted odds ratio 1.7, 95% CI 1.2-2.3).</p><p>The role of early extracorporeal membrane oxygenation (ECMO) support in preventing or improving severe PGD is not clear. Nonemergent use of ECMO in the posttransplant setting ("bridging") was not associated with grade 3 PGD at 48 or 72 hours or worsening survival in the LTOG cohort [<a href="#rid5">5</a>]. However, in patients with grade 3 PGD, those who initiated ECMO as a salvage strategy experienced slightly worse short-term and significantly worse long-term outcomes compared with those who did not. In addition, patients requiring venoarterial ECMO salvage had much higher mortality over the course of the study than those requiring venovenous ECMO salvage (37 versus 24 percent). Whether the mortality risk in patients with PGD requiring ECMO rescue is due to the severity of PGD (within grade 3), recipient severity of illness pretransplant, or deleterious effects of ECMO itself remains highly uncertain.</p><p class="headingAnchor" id="H29775931"><span class="h2">Chronic lung allograft dysfunction</span><span class="headingEndMark"> — </span>Several, but not all, published reports have found that patients who survive PGD are at increased risk for subsequent development of chronic lung allograft dysfunction (CLAD) [<a href="#rid4">4,25,144-147</a>]. In a retrospective cohort study of 334 lung transplant recipients, the severity of initial PGD correlated with the risk of bronchiolitis obliterans syndrome. (See  <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"</a>.)</p><p>The link between PGD and CLAD is not fully understood. Data suggest that severe early lung inflammation during PGD promotes the development of alloimmune responses. Additionally, lung injury exposes sequestered lung antigens such as collagen type V and subsequently promotes development of autoimmune responses that have been implicated in the pathogenesis of CLAD [<a href="#rid148">148,149</a>]. Plasma donor-derived cell free DNA, a biomarker for severity of lung injury, was shown to be associated with subsequent development of CLAD [<a href="#rid150">150</a>]. Thus, approaches to prevent PGD or attenuate severity may be important for improving long-term outcomes after transplantation.</p><p class="headingAnchor" id="H2432155781"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122278.html" rel="external">"Society guideline links: Lung transplantation"</a>.)</p><p class="headingAnchor" id="H876975783"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Primary graft dysfunction (PGD) after lung transplantation represents a multifactorial injury to the transplanted lung(s) that develops in the first 72 hours after lung transplantation. (See <a class="local">'Introduction'</a> above and <a class="local">'Risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The cardinal clinical manifestations of PGD are declining oxygenation and diffuse radiographic opacities; additional clinical findings may include decreased pulmonary compliance, increased pulmonary vascular resistance, and intrapulmonary shunting. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PGD is a diagnosis of exclusion to be made after assessment of volume status, ventilator settings, chest radiograph, echocardiogram, donor-recipient cross-match and screen for donor specific antibodies, bronchoscopy with an airway survey and bronchoalveolar lavage (BAL), and exclusion of infection. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The International Society of Heart Lung Transplantation (ISHLT) has proposed a grading system for the classification of PGD based on the ratio of arterial oxygen pressure to inspired oxygen concentration (PaO<sub>2</sub>/FiO<sub>2</sub>) ratio  (<a class="graphic graphic_table graphicRef78107" href="/z/d/graphic/78107.html" rel="external">table 1</a>). PGD is graded at four time points, every 24 hours for the first 72 hours after transplantation (T0, T24, T48, and T72 hours). (See <a class="local">'Definition and grading'</a> above.).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most patients with PGD that is less than grade 3 severity improve with conventional supportive treatment, including lung protective ventilation and optimal fluid management. Empiric broad spectrum antibiotics are routinely administered while awaiting microbiologic and histopathologic data. (See <a class="local">'Treatment'</a> above and <a class="local">'Initial supportive care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with more severe PGD grade 3 (ie, persistent difficulty with oxygenation and elevated pulmonary artery pressures), we suggest adding an inhaled pulmonary vasodilator such as nitric oxide (iNO) or <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Based on clinical experience, these agents reduce pulmonary artery pressures and improve oxygenation, although outcomes data are limited. (See <a class="local">'Refractory hypoxemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with severe PGD grade 3 and an inadequate response to optimal ventilator and fluid management and iNO/<a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">epoprostenol</a>, we recommend initiating extracorporeal membrane oxygenation (ECMO) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Some patients will stabilize with venovenous ECMO, although some patients will require venoarterial ECMO. Early initiation of ECMO support (within 24 hours) has a greater likelihood of success. (See <a class="local">'Refractory hypoxemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retransplantation for PGD is generally associated with a poor outcome and is avoided by most transplant centers. (See <a class="local">'Refractory hypoxemia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PGD appears to be a risk factor for subsequent development of chronic lung allograft dysfunction. (See <a class="local">'Chronic lung allograft dysfunction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Strategies to prevent PGD include use of adequate donor lung management and selection and optimization of lung preservation, storage, intraoperative management, and reperfusion techniques. (See <a class="local">'Prevention'</a> above and  <a class="medical medical_review" href="/z/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>.)</p><p></p><p class="headingAnchor" id="H92365476"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Elbert Trulock, MD, Marcelo Cypel, MD, MSc, FRCSC, Tom Waddell, MD, MSc, PhD, FRCS, FACS, and Shaf Keshavjee, MD, MSc, FRCSC, FACS, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1097.</a></li><li><a class="nounderline abstract_t">ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307:2526.</a></li><li><a class="nounderline abstract_t">Rice TW, Wheeler AP, Bernard GR, et al. Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest 2007; 132:410.</a></li><li><a class="nounderline abstract_t">Balsara KR, Krupnick AS, Bell JM, et al. A single-center experience of 1500 lung transplant patients. J Thorac Cardiovasc Surg 2018; 156:894.</a></li><li><a class="nounderline abstract_t">Cantu E, Diamond JM, Cevasco M, et al. Contemporary trends in PGD incidence, outcomes, and therapies. J Heart Lung Transplant 2022; 41:1839.</a></li><li><a class="nounderline abstract_t">Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187:527.</a></li><li><a class="nounderline abstract_t">Diamond JM, Arcasoy S, Kennedy CC, et al. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1104.</a></li><li><a class="nounderline abstract_t">Kreisel D, Krupnick AS, Puri V, et al. Short- and long-term outcomes of 1000 adult lung transplant recipients at a single center. J Thorac Cardiovasc Surg 2011; 141:215.</a></li><li><a class="nounderline abstract_t">Van Raemdonck D, Hartwig MG, Hertz MI, et al. Report of the ISHLT Working Group on primary lung graft dysfunction Part IV: Prevention and treatment: A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1121.</a></li><li><a class="nounderline abstract_t">Watts RP, Thom O, Fraser JF. Inflammatory signalling associated with brain dead organ donation: from brain injury to brain stem death and posttransplant ischaemia reperfusion injury. J Transplant 2013; 2013:521369.</a></li><li><a class="nounderline abstract_t">Kotloff RM, Blosser S, Fulda GJ, et al. Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement. Crit Care Med 2015; 43:1291.</a></li><li><a class="nounderline abstract_t">Potestio C, Jordan D, Kachulis B. Acute postoperative management after lung transplantation. Best Pract Res Clin Anaesthesiol 2017; 31:273.</a></li><li><a class="nounderline abstract_t">López-Sánchez M, Alvarez-Antoñán C, Arce-Mateos FP, et al. Single lung transplantation and fatal fat embolism acquired from the donor: management and literature review. Clin Transplant 2010; 24:133.</a></li><li><a class="nounderline abstract_t">Goodwin J, Tinckam K, denHollander N, et al. Transfusion-related acute lung injury (TRALI) in graft by blood donor antibodies against host leukocytes. J Heart Lung Transplant 2010; 29:1067.</a></li><li><a class="nounderline abstract_t">Natalini JG, Diamond JM. Primary Graft Dysfunction. Semin Respir Crit Care Med 2021; 42:368.</a></li><li><a class="nounderline abstract_t">Barklin A. Systemic inflammation in the brain-dead organ donor. Acta Anaesthesiol Scand 2009; 53:425.</a></li><li><a class="nounderline abstract_t">Lisman T, Leuvenink HG, Porte RJ, Ploeg RJ. Activation of hemostasis in brain dead organ donors: an observational study. J Thromb Haemost 2011; 9:1959.</a></li><li><a class="nounderline abstract_t">Kaneda H, Waddell TK, de Perrot M, et al. Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans. Am J Transplant 2006; 6:544.</a></li><li><a class="nounderline abstract_t">Schwarz P, Custódio G, Rheinheimer J, et al. Brain Death-Induced Inflammatory Activity is Similar to Sepsis-Induced Cytokine Release. Cell Transplant 2018; 27:1417.</a></li><li><a class="nounderline abstract_t">Fisher AJ, Donnelly SC, Hirani N, et al. Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation. Am J Respir Crit Care Med 2001; 163:259.</a></li><li><a class="nounderline abstract_t">Cypel M, Neyrinck A, Machuca TN. Ex vivo perfusion techniques: state of the art and potential applications. Intensive Care Med 2019; 45:354.</a></li><li><a class="nounderline abstract_t">Thabut G, Mal H, Cerrina J, et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med 2005; 171:786.</a></li><li><a class="nounderline abstract_t">Gelman AE, Fisher AJ, Huang HJ, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part III: Mechanisms: A 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1114.</a></li><li><a class="nounderline abstract_t">Laubach VE, Sharma AK. Mechanisms of lung ischemia-reperfusion injury. Curr Opin Organ Transplant 2016; 21:246.</a></li><li><a class="nounderline abstract_t">Porteous MK, Lee JC. Primary Graft Dysfunction After Lung Transplantation. Clin Chest Med 2017; 38:641.</a></li><li><a class="nounderline abstract_t">Scozzi D, Ibrahim M, Liao F, et al. Mitochondrial damage-associated molecular patterns released by lung transplants are associated with primary graft dysfunction. Am J Transplant 2019; 19:1464.</a></li><li><a class="nounderline abstract_t">Whitson BA, Nath DS, Johnson AC, et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006; 131:73.</a></li><li><a class="nounderline abstract_t">Diamond JM, Cantu E, Calfee CS, et al. The Impact of Donor Smoking on Primary Graft Dysfunction and Mortality after Lung Transplantation. Am J Respir Crit Care Med 2024; 209:91.</a></li><li><a class="nounderline abstract_t">Bonser RS, Taylor R, Collett D, et al. Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry. Lancet 2012; 380:747.</a></li><li><a class="nounderline abstract_t">Ware LB, Lee JW, Wickersham N, et al. Donor smoking is associated with pulmonary edema, inflammation and epithelial dysfunction in ex vivo human donor lungs. Am J Transplant 2014; 14:2295.</a></li><li><a class="nounderline abstract_t">Simou E, Leonardi-Bee J, Britton J. The Effect of Alcohol Consumption on the Risk of ARDS: A Systematic Review and Meta-Analysis. Chest 2018; 154:58.</a></li><li><a class="nounderline abstract_t">MacGowan GA, Dark JH, Corris PA, Nair AR. Effects of drug abuse, smoking and alcohol on donor hearts and lungs. Transpl Int 2019; 32:1019.</a></li><li><a class="nounderline abstract_t">Pelaez A, Mitchell PO, Shah NS, et al. The role of donor chronic alcohol abuse in the development of primary graft dysfunction in lung transplant recipients. Am J Med Sci 2015; 349:117.</a></li><li><a class="nounderline abstract_t">Lowery EM, Kuhlmann EA, Mahoney EL, et al. Heavy alcohol use in lung donors increases the risk for primary graft dysfunction. Alcohol Clin Exp Res 2014; 38:2853.</a></li><li><a class="nounderline abstract_t">Baldwin MR, Peterson ER, Easthausen I, et al. Donor age and early graft failure after lung transplantation: a cohort study. Am J Transplant 2013; 13:2685.</a></li><li><a class="nounderline abstract_t">Renard R, Girault A, Avramenko-Bouvier A, et al. Outcome of Lung Transplantation Using Grafts From Donors Over 65 Years of Age. Ann Thorac Surg 2021; 112:1142.</a></li><li><a class="nounderline abstract_t">Kuntz CL, Hadjiliadis D, Ahya VN, et al. Risk factors for early primary graft dysfunction after lung transplantation: a registry study. Clin Transplant 2009; 23:819.</a></li><li><a class="nounderline abstract_t">Alvarez A, Moreno P, Illana J, et al. Influence of donor-recipient gender mismatch on graft function and survival following lung transplantation. Interact Cardiovasc Thorac Surg 2013; 16:426.</a></li><li><a class="nounderline abstract_t">Eberlein M, Reed RM. Donor to recipient sizing in thoracic organ transplantation. World J Transplant 2016; 6:155.</a></li><li><a class="nounderline abstract_t">Eberlein M, Reed RM, Bolukbas S, et al. Lung size mismatch and primary graft dysfunction after bilateral lung transplantation. J Heart Lung Transplant 2015; 34:233.</a></li><li><a class="nounderline abstract_t">Ramendra R, Sage AT, Yeung J, et al. Triaging donor lungs based on a microaspiration signature that predicts adverse recipient outcome. J Heart Lung Transplant 2023; 42:456.</a></li><li><a class="nounderline abstract_t">Okamoto T, Niikawa H, Wheeler D, et al. Significance of Lung Weight in Cellular Ex Vivo Lung Perfusion. J Surg Res 2021; 260:190.</a></li><li><a class="nounderline abstract_t">Okamoto T, Ayyat KS, Sakanoue I, et al. Clinical significance of donor lung weight at procurement and during ex vivo lung perfusion. J Heart Lung Transplant 2022; 41:818.</a></li><li><a class="nounderline abstract_t">Jacob S, Courtwright A, El-Chemaly S, et al. Donor-acquired fat embolism syndrome after lung transplantation. Eur J Cardiothorac Surg 2016; 49:1344.</a></li><li class="breakAll">Oto T, Excell L, Griffiths AP, et al. The implications of pulmonary embolism in a multiorgan donor for subsequent pulmonary, renal, and cardiac transplantation. J Heart Lung Transplant 2008; 27:78.</li><li><a class="nounderline abstract_t">Liu Y, Liu Y, Su L, Jiang SJ. Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis. PLoS One 2014; 9:e92773.</a></li><li><a class="nounderline abstract_t">Shah RJ, Diamond JM, Cantu E, et al. Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation. Am J Transplant 2015; 15:2188.</a></li><li><a class="nounderline abstract_t">Porteous MK, Lee JC, Lederer DJ, et al. Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension. Ann Am Thorac Soc 2017; 14:1514.</a></li><li><a class="nounderline abstract_t">Anderson MR, Cantu E, Shashaty M, et al. Body Mass Index and Cause-Specific Mortality after Lung Transplantation in the United States. Ann Am Thorac Soc 2023; 20:825.</a></li><li><a class="nounderline abstract_t">Lederer DJ, Kawut SM, Wickersham N, et al. Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011; 184:1055.</a></li><li><a class="nounderline abstract_t">Anderson MR, Udupa JK, Edwin E, et al. Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study. J Heart Lung Transplant 2019; 38:1246.</a></li><li><a class="nounderline abstract_t">Diamond JM, Meyer NJ, Feng R, et al. Variation in PTX3 is associated with primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2012; 186:546.</a></li><li><a class="nounderline abstract_t">Diamond JM, Akimova T, Kazi A, et al. Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction. Am J Respir Crit Care Med 2014; 189:567.</a></li><li><a class="nounderline abstract_t">Cantu E, Suzuki Y, Diamond JM, et al. Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. Am J Transplant 2016; 16:833.</a></li><li><a class="nounderline abstract_t">Porteous MK, Ky B, Kirkpatrick JN, et al. Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant. Am J Respir Crit Care Med 2016; 193:1392.</a></li><li><a class="nounderline abstract_t">Li D, Weinkauf J, Hirji A, et al. Elevated pre-transplant left ventricular end-diastolic pressure increases primary graft dysfunction risk in double lung transplant recipients. J Heart Lung Transplant 2019; 38:710.</a></li><li><a class="nounderline abstract_t">de Perrot M, McRae K. Left ventricular lusitropy and primary graft dysfunction in lung transplantation. J Heart Lung Transplant 2019; 38:719.</a></li><li><a class="nounderline abstract_t">Park JE, Kim CY, Park MS, et al. Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients. BMC Pulm Med 2018; 18:45.</a></li><li><a class="nounderline abstract_t">Bharat A, Kreisel D. Immunopathogenesis of Primary Graft Dysfunction After Lung Transplantation. Ann Thorac Surg 2018; 105:671.</a></li><li><a class="nounderline abstract_t">Akbarpour M, Wu Q, Liu X, et al. Clinical relevance of lung-restricted antibodies in lung transplantation. Hum Immunol 2019; 80:595.</a></li><li><a class="nounderline abstract_t">Bermudez CA, Shiose A, Esper SA, et al. Outcomes of intraoperative venoarterial extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation. Ann Thorac Surg 2014; 98:1936.</a></li><li><a class="nounderline abstract_t">Hoechter DJ, Shen YM, Kammerer T, et al. Extracorporeal Circulation During Lung Transplantation Procedures: A Meta-Analysis. ASAIO J 2017; 63:551.</a></li><li><a class="nounderline abstract_t">Ohsumi A, Date H. Perioperative circulatory support for lung transplantation. Gen Thorac Cardiovasc Surg 2021; 69:631.</a></li><li><a class="nounderline abstract_t">Magouliotis DE, Tasiopoulou VS, Svokos AA, et al. Extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a meta-analysis. Gen Thorac Cardiovasc Surg 2018; 66:38.</a></li><li><a class="nounderline abstract_t">Subramaniam K, Loor G, Chan EG, et al. Intraoperative Red Blood Cell Transfusion and Primary Graft Dysfunction After Lung Transplantation. Transplantation 2023; 107:1573.</a></li><li><a class="nounderline abstract_t">Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180:1010.</a></li><li><a class="nounderline abstract_t">Borders CF, Suzuki Y, Lasky J, et al. Massive donor transfusion potentially increases recipient mortality after lung transplantation. J Thorac Cardiovasc Surg 2017; 153:1197.</a></li><li><a class="nounderline abstract_t">Yeung JC, Krueger T, Yasufuku K, et al. Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. Lancet Respir Med 2017; 5:119.</a></li><li><a class="nounderline abstract_t">Vandervelde CM, Vos R, Vanluyten C, et al. Impact of anastomosis time during lung transplantation on primary graft dysfunction. Am J Transplant 2022; 22:1418.</a></li><li><a class="nounderline abstract_t">Tague LK, Bedair B, Witt C, et al. Lung protective ventilation based on donor size is associated with a lower risk of severe primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2021; 40:1212.</a></li><li><a class="nounderline abstract_t">Force SD, Miller DL, Pelaez A, et al. Outcomes of delayed chest closure after bilateral lung transplantation. Ann Thorac Surg 2006; 81:2020.</a></li><li><a class="nounderline abstract_t">Shigemura N, Orhan Y, Bhama JK, et al. Delayed chest closure after lung transplantation: techniques, outcomes, and strategies. J Heart Lung Transplant 2014; 33:741.</a></li><li><a class="nounderline abstract_t">Kim SY, Jeong SJ, Lee JG, et al. Critical Care after Lung Transplantation. Acute Crit Care 2018; 33:206.</a></li><li><a class="nounderline abstract_t">Geube MA, Perez-Protto SE, McGrath TL, et al. Increased Intraoperative Fluid Administration Is Associated with Severe Primary Graft Dysfunction After Lung Transplantation. Anesth Analg 2016; 122:1081.</a></li><li><a class="nounderline abstract_t">Schulman LL, Anandarangam T, Leibowitz DW, et al. Four-year prospective study of pulmonary venous thrombosis after lung transplantation. J Am Soc Echocardiogr 2001; 14:806.</a></li><li><a class="nounderline abstract_t">Leibowitz DW, Smith CR, Michler RE, et al. Incidence of pulmonary vein complications after lung transplantation: a prospective transesophageal echocardiographic study. J Am Coll Cardiol 1994; 24:671.</a></li><li><a class="nounderline abstract_t">Batra K, Chamarthy MR, Reddick M, et al. Diagnosis and interventions of vascular complications in lung transplant. Cardiovasc Diagn Ther 2018; 8:378.</a></li><li><a class="nounderline abstract_t">Jokerst C, Sirajuddin A, Mohammed TL. Imaging the Complications of Lung Transplantation. Radiol Clin North Am 2016; 54:355.</a></li><li><a class="nounderline abstract_t">Le Page AK, Kainer G, Glanville AR, et al. Influenza B virus transmission in recipients of kidney and lung transplants from an infected donor. Transplantation 2010; 90:99.</a></li><li><a class="nounderline abstract_t">David A, Liberge R, Corne F, Frampas E. Whole-lung torsion complicating double lung transplantation: CT features. Diagn Interv Imaging 2016; 97:927.</a></li><li><a class="nounderline abstract_t">Bharat A, Saini D, Steward N, et al. Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection. Ann Thorac Surg 2010; 90:1094.</a></li><li><a class="nounderline abstract_t">Shah RJ, Diamond JM. Primary Graft Dysfunction (PGD) Following Lung Transplantation. Semin Respir Crit Care Med 2018; 39:148.</a></li><li><a class="nounderline abstract_t">Pasero D, Martin EL, Davi A, et al. The effects of inhaled nitric oxide after lung transplantation. Minerva Anestesiol 2010; 76:353.</a></li><li><a class="nounderline abstract_t">Fiser SM, Cope JT, Kron IL, et al. Aerosolized prostacyclin (epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation. J Thorac Cardiovasc Surg 2001; 121:981.</a></li><li><a class="nounderline abstract_t">Khan TA, Schnickel G, Ross D, et al. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg 2009; 138:1417.</a></li><li><a class="nounderline abstract_t">Shargall Y, Guenther G, Ahya VN, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J Heart Lung Transplant 2005; 24:1489.</a></li><li><a class="nounderline abstract_t">Wigfield CH, Lindsey JD, Steffens TG, et al. Early institution of extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation improves outcome. J Heart Lung Transplant 2007; 26:331.</a></li><li><a class="nounderline abstract_t">Meyers BF, Sundt TM 3rd, Henry S, et al. Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation. J Thorac Cardiovasc Surg 2000; 120:20.</a></li><li><a class="nounderline abstract_t">Harano T, Ryan JP, Morrell MR, et al. Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction After Lung Transplantation. ASAIO J 2021; 67:1071.</a></li><li><a class="nounderline abstract_t">Hartwig MG, Walczak R, Lin SS, Davis RD. Improved survival but marginal allograft function in patients treated with extracorporeal membrane oxygenation after lung transplantation. Ann Thorac Surg 2012; 93:366.</a></li><li><a class="nounderline abstract_t">Bermudez CA, Adusumilli PS, McCurry KR, et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: long-term survival. Ann Thorac Surg 2009; 87:854.</a></li><li><a class="nounderline abstract_t">Boffini M, Simonato E, Ricci D, et al. Extracorporeal membrane oxygenation after lung transplantation: risk factors and outcomes analysis. Ann Cardiothorac Surg 2019; 8:54.</a></li><li><a class="nounderline abstract_t">Bellier J, Lhommet P, Bonnette P, et al. Extracorporeal membrane oxygenation for grade 3 primary graft dysfunction after lung transplantation: Long-term outcomes. Clin Transplant 2019; 33:e13480.</a></li><li><a class="nounderline abstract_t">Aigner C, Jaksch P, Taghavi S, et al. Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases. J Heart Lung Transplant 2008; 27:60.</a></li><li><a class="nounderline abstract_t">Kawut SM, Lederer DJ, Keshavjee S, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008; 177:114.</a></li><li><a class="nounderline abstract_t">Sommer W, Ius F, Kühn C, et al. Technique and Outcomes of Less Invasive Lung Retransplantation. Transplantation 2018; 102:530.</a></li><li><a class="nounderline abstract_t">Collaud S, Benden C, Ganter C, et al. Extracorporeal Life Support as Bridge to Lung Retransplantation: A Multicenter Pooled Data Analysis. Ann Thorac Surg 2016; 102:1680.</a></li><li><a class="nounderline abstract_t">Halloran K, Aversa M, Tinckam K, et al. Comprehensive outcomes after lung retransplantation: A single-center review. Clin Transplant 2018; 32:e13281.</a></li><li><a class="nounderline abstract_t">Grimm JC, Valero V 3rd, Kilic A, et al. Association Between Prolonged Graft Ischemia and Primary Graft Failure or Survival Following Lung Transplantation. JAMA Surg 2015; 150:547.</a></li><li><a class="nounderline abstract_t">Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364:1431.</a></li><li><a class="nounderline abstract_t">Divithotawela C, Cypel M, Martinu T, et al. Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion. JAMA Surg 2019; 154:1143.</a></li><li><a class="nounderline abstract_t">Okamoto T, Wheeler D, Farver CF, McCurry KR. Transplant Suitability of Rejected Human Donor Lungs With Prolonged Cold Ischemia Time in Low-Flow Acellular and High-Flow Cellular Ex Vivo Lung Perfusion Systems. Transplantation 2019; 103:1799.</a></li><li><a class="nounderline abstract_t">Leiva-Juárez MM, Urso A, Arango Tomás E, et al. Extended post-ex vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study. J Heart Lung Transplant 2020; 39:954.</a></li><li><a class="nounderline abstract_t">Warnecke G, Van Raemdonck D, Smith MA, et al. Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study. Lancet Respir Med 2018; 6:357.</a></li><li><a class="nounderline abstract_t">Pierre AF, DeCampos KN, Liu M, et al. Rapid reperfusion causes stress failure in ischemic rat lungs. J Thorac Cardiovasc Surg 1998; 116:932.</a></li><li><a class="nounderline abstract_t">Hidalgo MA, Shah KA, Fuller BJ, Green CJ. Cold ischemia-induced damage to vascular endothelium results in permeability alterations in transplanted lungs. J Thorac Cardiovasc Surg 1996; 112:1027.</a></li><li><a class="nounderline abstract_t">Hall SM, Odom N, McGregor CG, Haworth SG. Transient ultrastructural injury and repair of pulmonary capillaries in transplanted rat lung: effect of preservation and reperfusion. Am J Respir Cell Mol Biol 1992; 7:49.</a></li><li><a class="nounderline abstract_t">Bhabra MS, Hopkinson DN, Shaw TE, Hooper TL. Critical importance of the first 10 minutes of lung graft reperfusion after hypothermic storage. Ann Thorac Surg 1996; 61:1631.</a></li><li><a class="nounderline abstract_t">Botha P, Jeyakanthan M, Rao JN, et al. Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2007; 26:1199.</a></li><li><a class="nounderline abstract_t">Meade MO, Granton JT, Matte-Martyn A, et al. A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation. Am J Respir Crit Care Med 2003; 167:1483.</a></li><li><a class="nounderline abstract_t">Perrin G, Roch A, Michelet P, et al. Inhaled nitric oxide does not prevent pulmonary edema after lung transplantation measured by lung water content: a randomized clinical study. Chest 2006; 129:1024.</a></li><li><a class="nounderline abstract_t">Moreno I, Vicente R, Mir A, et al. Effects of inhaled nitric oxide on primary graft dysfunction in lung transplantation. Transplant Proc 2009; 41:2210.</a></li><li><a class="nounderline abstract_t">de Perrot M, Fischer S, Liu M, et al. Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti-inflammatory cytokines. Transplantation 2001; 72:1505.</a></li><li><a class="nounderline abstract_t">Chiang CH, Wu K, Yu CP, et al. Hypothermia and prostaglandin E(1) produce synergistic attenuation of ischemia-reperfusion lung injury. Am J Respir Crit Care Med 1999; 160:1319.</a></li><li><a class="nounderline abstract_t">Lee SH, Lee JG, Lee CY, et al. Effects of intraoperative inhaled iloprost on primary graft dysfunction after lung transplantation: A retrospective single center study. Medicine (Baltimore) 2016; 95:e3975.</a></li><li><a class="nounderline abstract_t">Ghadimi K, Cappiello J, Cooter-Wright M, et al. Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant: A Randomized Clinical Trial. JAMA Surg 2022; 157:e215856.</a></li><li><a class="nounderline abstract_t">Hsin M, Au T. Ex vivo lung perfusion: a potential platform for molecular diagnosis and ex vivo organ repair. J Thorac Dis 2018; 10:S1871.</a></li><li><a class="nounderline abstract_t">Shaver CM, Ware LB. Primary graft dysfunction: pathophysiology to guide new preventive therapies. Expert Rev Respir Med 2017; 11:119.</a></li><li><a class="nounderline abstract_t">Tane S, Noda K, Shigemura N. Ex Vivo Lung Perfusion: A Key Tool for Translational Science in the Lungs. Chest 2017; 151:1220.</a></li><li><a class="nounderline abstract_t">Iske J, Hinze CA, Salman J, et al. The potential of ex vivo lung perfusion on improving organ quality and ameliorating ischemia reperfusion injury. Am J Transplant 2021; 21:3831.</a></li><li><a class="nounderline abstract_t">Lau CL, Beller JP, Boys JA, et al. Adenosine A2A receptor agonist (regadenoson) in human lung transplantation. J Heart Lung Transplant 2020; 39:563.</a></li><li><a class="nounderline abstract_t">Ochs M, Nenadic I, Fehrenbach A, et al. Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion. Am J Respir Crit Care Med 1999; 160:718.</a></li><li><a class="nounderline abstract_t">Hohlfeld JM, Strüber M, Ahlf K, et al. Exogenous surfactant improves survival and surfactant function in ischaemia-reperfusion injury in minipigs. Eur Respir J 1999; 13:1037.</a></li><li><a class="nounderline abstract_t">Koletsis E, Chatzimichalis A, Fotopoulos V, et al. Donor lung pretreatment with surfactant in experimental transplantation preserves graft hemodynamics and alveolar morphology. Exp Biol Med (Maywood) 2003; 228:540.</a></li><li><a class="nounderline abstract_t">Kermeen FD, McNeil KD, Fraser JF, et al. Resolution of severe ischemia-reperfusion injury post-lung transplantation after administration of endobronchial surfactant. J Heart Lung Transplant 2007; 26:850.</a></li><li><a class="nounderline abstract_t">Amital A, Shitrit D, Raviv Y, et al. The use of surfactant in lung transplantation. Transplantation 2008; 86:1554.</a></li><li><a class="nounderline abstract_t">Strüber M, Fischer S, Niedermeyer J, et al. Effects of exogenous surfactant instillation in clinical lung transplantation: a prospective, randomized trial. J Thorac Cardiovasc Surg 2007; 133:1620.</a></li><li><a class="nounderline abstract_t">Ali A, Pettenuzzo T, Ramadan K, et al. Surfactant therapy in lung transplantation: A systematic review and meta-analysis. Transplant Rev (Orlando) 2021; 35:100637.</a></li><li><a class="nounderline abstract_t">Kulkarni HS, Ramphal K, Ma L, et al. Local complement activation is associated with primary graft dysfunction after lung transplantation. JCI Insight 2020; 5.</a></li><li><a class="nounderline abstract_t">Keshavjee S, Davis RD, Zamora MR, et al. A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings. J Thorac Cardiovasc Surg 2005; 129:423.</a></li><li><a class="nounderline abstract_t">Sommer W, Tudorache I, Kühn C, et al. C1-esterase-inhibitor for primary graft dysfunction in lung transplantation. Transplantation 2014; 97:1185.</a></li><li><a class="nounderline abstract_t">Aigner C, Slama A, Barta M, et al. Treatment of primary graft dysfunction after lung transplantation with orally inhaled AP301: A prospective, randomized pilot study. J Heart Lung Transplant 2017.</a></li><li><a class="nounderline abstract_t">Dharmarajan S, Hayama M, Ishiyama T, et al. Repertaxin, a novel IL-8 receptor inhibitor, ameliorates ischemia-reperfusion injury after experimental lung transplantation. J Heart Lung Transplant 2005; 24:S79.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/NCT00224406?cond=lung+transplantation+primary+graft+dysfunction&amp;draw=2&amp;rank=7 (Accessed on February 22, 2022).</li><li><a class="nounderline abstract_t">Cypel M, Liu M, Rubacha M, et al. Functional repair of human donor lungs by IL-10 gene therapy. Sci Transl Med 2009; 1:4ra9.</a></li><li><a class="nounderline abstract_t">Shirley JL, de Jong YP, Terhorst C, Herzog RW. Immune Responses to Viral Gene Therapy Vectors. Mol Ther 2020; 28:709.</a></li><li><a class="nounderline abstract_t">Mordant P, Nakajima D, Kalaf R, et al. Mesenchymal stem cell treatment is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor lungs after 18-hour preservation. J Heart Lung Transplant 2016; 35:1245.</a></li><li><a class="nounderline abstract_t">Nakajima D, Watanabe Y, Ohsumi A, et al. Mesenchymal stromal cell therapy during ex vivo lung perfusion ameliorates ischemia-reperfusion injury in lung transplantation. J Heart Lung Transplant 2019; 38:1214.</a></li><li><a class="nounderline abstract_t">Nykänen AI, Mariscal A, Duong A, et al. Engineered mesenchymal stromal cell therapy during human lung ex vivo lung perfusion is compromised by acidic lung microenvironment. Mol Ther Methods Clin Dev 2021; 23:184.</a></li><li><a class="nounderline abstract_t">Richeldi L, Baldi F, Pasciuto G, et al. Current and Future Idiopathic Pulmonary Fibrosis Therapy. Am J Med Sci 2019; 357:370.</a></li><li><a class="nounderline abstract_t">Saito M, Chen-Yoshikawa TF, Suetsugu K, et al. Pirfenidone alleviates lung ischemia-reperfusion injury in a rat model. J Thorac Cardiovasc Surg 2019; 158:289.</a></li><li><a class="nounderline abstract_t">Veit T, Leuschner G, Sisic A, et al. Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation. Am J Transplant 2019; 19:2358.</a></li><li><a class="nounderline abstract_t">Prekker ME, Nath DS, Walker AR, et al. Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2006; 25:371.</a></li><li><a class="nounderline abstract_t">Daud SA, Yusen RD, Meyers BF, et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2007; 175:507.</a></li><li><a class="nounderline abstract_t">Whitson BA, Prekker ME, Herrington CS, et al. Primary graft dysfunction and long-term pulmonary function after lung transplantation. J Heart Lung Transplant 2007; 26:1004.</a></li><li><a class="nounderline abstract_t">Fiser SM, Tribble CG, Long SM, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002; 73:1041.</a></li><li><a class="nounderline abstract_t">Fisher AJ, Wardle J, Dark JH, Corris PA. Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS). J Heart Lung Transplant 2002; 21:1206.</a></li><li><a class="nounderline abstract_t">Hachem RR, Tiriveedhi V, Patterson GA, et al. Antibodies to K-α 1 tubulin and collagen V are associated with chronic rejection after lung transplantation. Am J Transplant 2012; 12:2164.</a></li><li><a class="nounderline abstract_t">Agashe VV, Burlingham WJ. Autoimmune Reactivity in Graft Injury: Player or Bystander? Curr Transplant Rep 2015; 2:211.</a></li><li><a class="nounderline abstract_t">Keller M, Bush E, Diamond JM, et al. Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD). J Heart Lung Transplant 2021; 40:488.</a></li></ol></div><div id="topicVersionRevision">Topic 4663 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28942784" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22797452" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Acute respiratory distress syndrome: the Berlin Definition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17573487" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29891245" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A single-center experience of 1500 lung transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36216694" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Contemporary trends in PGD incidence, outcomes, and therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23306540" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical risk factors for primary graft dysfunction after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28802530" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21093882" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Short- and long-term outcomes of 1000 adult lung transplant recipients at a single center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28784325" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Report of the ISHLT Working Group on primary lung graft dysfunction Part IV: Prevention and treatment: A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23691272" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Inflammatory signalling associated with brain dead organ donation: from brain injury to brain stem death and posttransplant ischaemia reperfusion injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25978154" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Management of the Potential Organ Donor in the ICU: Society of Critical Care Medicine/American College of Chest Physicians/Association of Organ Procurement Organizations Consensus Statement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29110799" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Acute postoperative management after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19888997" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Single lung transplantation and fatal fat embolism acquired from the donor: management and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20627626" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Transfusion-related acute lung injury (TRALI) in graft by blood donor antibodies against host leukocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34030200" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Primary Graft Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19226294" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Systemic inflammation in the brain-dead organ donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21762465" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Activation of hemostasis in brain dead organ donors: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16468964" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Pre-implantation multiple cytokine mRNA expression analysis of donor lung grafts predicts survival after lung transplantation in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30235942" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Brain Death-Induced Inflammatory Activity is Similar to Sepsis-Induced Cytokine Release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11208654" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Elevated levels of interleukin-8 in donor lungs is associated with early graft failure after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30805660" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ex vivo perfusion techniques: state of the art and potential applications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15665320" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Graft ischemic time and outcome of lung transplantation: a multicenter analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28818404" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part III: Mechanisms: A 2016 Consensus Group Statement of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26945320" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mechanisms of lung ischemia-reperfusion injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29128015" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Primary Graft Dysfunction After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30582269" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mitochondrial damage-associated molecular patterns released by lung transplants are associated with primary graft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16399297" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Risk factors for primary graft dysfunction after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37734031" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The Impact of Donor Smoking on Primary Graft Dysfunction and Mortality after Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22647758" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effect of donor smoking on survival after lung transplantation: a cohort study of a prospective registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25146497" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Donor smoking is associated with pulmonary edema, inflammation and epithelial dysfunction in ex vivo human donor lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29288645" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The Effect of Alcohol Consumption on the Risk of ARDS: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31172575" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Effects of drug abuse, smoking and alcohol on donor hearts and lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25310510" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The role of donor chronic alcohol abuse in the development of primary graft dysfunction in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25421520" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Heavy alcohol use in lung donors increases the risk for primary graft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24034167" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Donor age and early graft failure after lung transplantation: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33171173" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Outcome of Lung Transplantation Using Grafts From Donors Over 65 Years of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19239481" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk factors for early primary graft dysfunction after lung transplantation: a registry study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23322094" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Influence of donor-recipient gender mismatch on graft function and survival following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27011913" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Donor to recipient sizing in thoracic organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25447586" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Lung size mismatch and primary graft dysfunction after bilateral lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36710092" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Triaging donor lungs based on a microaspiration signature that predicts adverse recipient outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33348170" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Significance of Lung Weight in Cellular Ex Vivo Lung Perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35307267" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Clinical significance of donor lung weight at procurement and during ex vivo lung perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26468269" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Donor-acquired fat embolism syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26468269" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Donor-acquired fat embolism syndrome after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24658073" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Recipient-related clinical risk factors for primary graft dysfunction after lung transplantation: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25877792" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Objective Estimates Improve Risk Stratification for Primary Graft Dysfunction after Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28719755" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical Risk Factors and Prognostic Model for Primary Graft Dysfunction after Lung Transplantation in Patients with Pulmonary Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36996331" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Body Mass Index and Cause-Specific Mortality after Lung Transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21799077" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Obesity and primary graft dysfunction after lung transplantation: the Lung Transplant Outcomes Group Obesity Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31474492" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Adipose tissue quantification and primary graft dysfunction after lung transplantation: The Lung Transplant Body Composition study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22822025" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Variation in PTX3 is associated with primary graft dysfunction after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24467603" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Genetic variation in the prostaglandin E2 pathway is associated with primary graft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26663441" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26745666" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Diastolic Dysfunction Increases the Risk of Primary Graft Dysfunction after Lung Transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30850154" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Elevated pre-transplant left ventricular end-diastolic pressure increases primary graft dysfunction risk in double lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30982738" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Left ventricular lusitropy and primary graft dysfunction in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29529999" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Prevalence of pre-transplant anti-HLA antibodies and their impact on outcomes in lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29455798" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Immunopathogenesis of Primary Graft Dysfunction After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31078336" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Clinical relevance of lung-restricted antibodies in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25443002" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Outcomes of intraoperative venoarterial extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28257296" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Extracorporeal Circulation During Lung Transplantation Procedures: A Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33666866" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Perioperative circulatory support for lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28918471" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36959119" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Intraoperative Red Blood Cell Transfusion and Primary Graft Dysfunction After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19661249" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28073574" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Massive donor transfusion potentially increases recipient mortality after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27866861" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35029023" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Impact of anastomosis time during lung transplantation on primary graft dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34353713" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Lung protective ventilation based on donor size is associated with a lower risk of severe primary graft dysfunction after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16731123" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Outcomes of delayed chest closure after bilateral lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24726683" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Delayed chest closure after lung transplantation: techniques, outcomes, and strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31723887" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Critical Care after Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991618" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Increased Intraoperative Fluid Administration Is Associated with Severe Primary Graft Dysfunction After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11490329" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Four-year prospective study of pulmonary venous thrombosis after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8077537" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Incidence of pulmonary vein complications after lung transplantation: a prospective transesophageal echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30057884" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Diagnosis and interventions of vascular complications in lung transplant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26896229" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Imaging the Complications of Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20606569" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Influenza B virus transmission in recipients of kidney and lung transplants from an infected donor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27421675" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Whole-lung torsion complicating double lung transplantation: CT features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20868794" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Antibodies to self-antigens predispose to primary lung allograft dysfunction and chronic rejection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590671" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Primary Graft Dysfunction (PGD) Following Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20395898" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The effects of inhaled nitric oxide after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11326243" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Aerosolized prostacyclin (epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19931670" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16210120" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403473" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Early institution of extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation improves outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10884650" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Selective use of extracorporeal membrane oxygenation is warranted after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33470638" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction After Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21962264" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Improved survival but marginal allograft function in patients treated with extracorporeal membrane oxygenation after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19231405" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: long-term survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30854312" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Extracorporeal membrane oxygenation after lung transplantation: risk factors and outcomes analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30657612" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Extracorporeal membrane oxygenation for grade 3 primary graft dysfunction after lung transplantation: Long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18187088" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Pulmonary retransplantation: is it worth the effort? A long-term analysis of 46 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17901410" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Outcomes after lung retransplantation in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28787308" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Technique and Outcomes of Less Invasive Lung Retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27424471" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Extracorporeal Life Support as Bridge to Lung Retransplantation: A Multicenter Pooled Data Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29754418" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Comprehensive outcomes after lung retransplantation: A single-center review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25874575" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Association Between Prolonged Graft Ischemia and Primary Graft Failure or Survival Following Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21488765" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Normothermic ex vivo lung perfusion in clinical lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31596484" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30801532" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Transplant Suitability of Rejected Human Donor Lungs With Prolonged Cold Ischemia Time in Low-Flow Acellular and High-Flow Cellular Ex Vivo Lung Perfusion Systems.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32475748" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Extended post-ex vivo lung perfusion cold preservation predicts primary graft dysfunction and mortality: Results from a multicentric study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29650408" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Normothermic ex-vivo preservation with the portable Organ Care System Lung device for bilateral lung transplantation (INSPIRE): a randomised, open-label, non-inferiority, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9832683" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Rapid reperfusion causes stress failure in ischemic rat lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8873730" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Cold ischemia-induced damage to vascular endothelium results in permeability alterations in transplanted lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1627336" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Transient ultrastructural injury and repair of pulmonary capillaries in transplanted rat lung: effect of preservation and reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8651760" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Critical importance of the first 10 minutes of lung graft reperfusion after hypothermic storage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18022088" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Inhaled nitric oxide for modulation of ischemia-reperfusion injury in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12770854" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A randomized trial of inhaled nitric oxide to prevent ischemia-reperfusion injury after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16608953" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Inhaled nitric oxide does not prevent pulmonary edema after lung transplantation measured by lung water content: a randomized clinical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19715875" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Effects of inhaled nitric oxide on primary graft dysfunction in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11707737" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Prostaglandin E1 protects lung transplants from ischemia-reperfusion injury: a shift from pro- to anti-inflammatory cytokines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10508824" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Hypothermia and prostaglandin E(1) produce synergistic attenuation of ischemia-reperfusion lung injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27399072" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Effects of intraoperative inhaled iloprost on primary graft dysfunction after lung transplantation: A retrospective single center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34787647" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Inhaled Pulmonary Vasodilator Therapy in Adult Lung Transplant: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30026974" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Ex vivo lung perfusion: a potential platform for molecular diagnosis and ex vivo organ repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28074663" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Primary graft dysfunction: pathophysiology to guide new preventive therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28238726" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Ex Vivo Lung Perfusion: A Key Tool for Translational Science in the Lungs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34355495" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : The potential of ex vivo lung perfusion on improving organ quality and ameliorating ischemia reperfusion injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32503727" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Adenosine A2A receptor agonist (regadenoson) in human lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430751" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Ultrastructural alterations in intraalveolar surfactant subtypes after experimental ischemia and reperfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10414401" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Exogenous surfactant improves survival and surfactant function in ischaemia-reperfusion injury in minipigs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12709583" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Donor lung pretreatment with surfactant in experimental transplantation preserves graft hemodynamics and alveolar morphology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17692791" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Resolution of severe ischemia-reperfusion injury post-lung transplantation after administration of endobronchial surfactant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19077889" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The use of surfactant in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17532965" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Effects of exogenous surfactant instillation in clinical lung transplantation: a prospective, randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34224988" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Surfactant therapy in lung transplantation: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32750037" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Local complement activation is associated with primary graft dysfunction after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15678055" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A randomized, placebo-controlled trial of complement inhibition in ischemia-reperfusion injury after lung transplantation in human beings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24573112" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : C1-esterase-inhibitor for primary graft dysfunction in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29055604" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Treatment of primary graft dysfunction after lung transplantation with orally inhaled AP301: A prospective, randomized pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Repertaxin, a novel IL-8 receptor inhibitor, ameliorates ischemia-reperfusion injury after experimental lung transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Repertaxin, a novel IL-8 receptor inhibitor, ameliorates ischemia-reperfusion injury after experimental lung transplantation</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20368171" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Functional repair of human donor lungs by IL-10 gene therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31968213" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Immune Responses to Viral Gene Therapy Vectors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27444694" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Mesenchymal stem cell treatment is associated with decreased perfusate concentration of interleukin-8 during ex vivo perfusion of donor lungs after 18-hour preservation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31474491" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Mesenchymal stromal cell therapy during ex vivo lung perfusion ameliorates ischemia-reperfusion injury in lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34703841" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Engineered mesenchymal stromal cell therapy during human lung ex vivo lung perfusion is compromised by acidic lung microenvironment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31010462" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Current and Future Idiopathic Pulmonary Fibrosis Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30385019" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Pirfenidone alleviates lung ischemia-reperfusion injury in a rat model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30942945" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Pirfenidone exerts beneficial effects in patients with IPF undergoing single lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16563963" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Validation of the proposed International Society for Heart and Lung Transplantation grading system for primary graft dysfunction after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17158279" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17919620" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Primary graft dysfunction and long-term pulmonary function after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11996238" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12431494" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Non-immune acute graft injury after lung transplantation and the risk of subsequent bronchiolitis obliterans syndrome (BOS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22568593" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Antibodies to K-α1 tubulin and collagen V are associated with chronic rejection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29057202" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Autoimmune Reactivity in Graft Injury: Player or Bystander?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33814284" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Use of donor-derived-cell-free DNA as a marker of early allograft injury in primary graft dysfunction (PGD) to predict the risk of chronic lung allograft dysfunction (CLAD).</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
